Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...
SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
After I removed the expectation that every note had to serve a larger system, Obsidian stopped feeling so complicated, and ...
XDA Developers on MSN
I'm sick of proprietary notetaking tools when plain text is simply better
Most proprietary note-taking apps try to solve every single problem and therefore keep adding more features. Each one has ...
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback